Drugs / Pneumococcal Vaccine, Polyvalent (23-valent)
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT00496093 | Oct 2005 → Jan 2006 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT00013871 | ? → Nov 2004 | HIV infectious disease, hepatitis B virus infection, measles, pertussis +1 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| — | NCT00001080 | — | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT00000829 Background | ? → Oct 1999 | HIV infectious disease, pneumococcal infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| — | NCT00034086 Background | ? → Jun 2006 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pneumococcal Vaccine, Polyvalent (23-valent) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00034086 ↗ |
| Known as | PNU-IMUNE 23 | “Additionally, patients receive PNU-IMUNE 23 ( pneumococcal polyvalent vaccine ) at 24 months of age.” NCT00000829 ↗ |
| Modality | Vaccine | “pneumococcal polyvalent vaccine” NCT00000829 ↗ |
| Route | Intramuscular | “by intramuscular (deltoid) injection” NCT00496093 ↗ |